ERBB2 and neoplasm: As expected, these findings paralleled what observed for sTILs both at baseline and day 15, for which however the difference between HR− and HR+ tumours was only significant after 2 weeks of anti-HER2 treatment (median sTILs at day 15 20% vs 10% in HR− and HR+ tumours, respectively, P < 0.001).